A.R.T. Advisors’s Tvardi Therapeutics TVRD Stock Holding History

A.R.T. Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-659	Closed	-$382K	–	1043
2019 Q4	$382K	Buy	+659	New	+$462K	0.02%	950
2019 Q1	–	Sell	-459	Closed	-$215K	–	1675
2018 Q4	$215K	Sell	459 -17	-4%	-$11K	0.01%	1035
2018 Q3	$410K	Sell	476 -891	-65%	-$643K	0.02%	931
2018 Q2	$942K	Buy	+1,367	New	+$695K	0.04%	655
2018 Q1	–	Sell	-447	Closed	-$197K	–	1798
2017 Q4	$197K	Sell	447 -4,820	-92%	-$2.2M	0.01%	1171
2017 Q3	$2.6M	Buy	+5,267	New	+$2.64M	0.13%	201
2016 Q2	–	Sell	-3,870	Closed	-$866K	–	1689
2016 Q1	$866K	Buy	3,870 +3,439	+798%	+$1.03M	0.04%	644
2015 Q4	$261K	Sell	431 -2,245	-84%	-$1.23M	0.01%	1109
2015 Q3	$1.38M	Buy	+2,676	New	+$1.79M	0.05%	516
2014 Q4	–	Sell	-451	Closed	-$136K	–	1701
2014 Q3	$136K	Buy	+451	New	+$185K	0.01%	1174

Other funds holding TVRD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

A.R.T. Advisors's TVRD Position: Q1 2020 in Review

A.R.T. Advisors sold out of Tvardi Therapeutics (TVRD) in Q1 2020, closing a stake of 659 shares — an estimated $382K sold.

A.R.T. Advisors first reported a position in TVRD in Q3 2014 and held it in 10 quarters. The position peaked at $2.6M in Q3 2017. 133 funds tracked by Wall St. Rank hold TVRD as of Q1 2020.

A.R.T. Advisors reported no remaining Tvardi Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 659 Tvardi Therapeutics shares in Q1 2020, an estimated $382K.
A.R.T. Advisors first reported a position in Tvardi Therapeutics in Q3 2014 and held it in 10 quarters.
A.R.T. Advisors's Tvardi Therapeutics position peaked at $2.6M in Q3 2017.
133 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.